Key Highlights
- Veravas partners with Phanes Biotech to co-develop a blood-based Alzheimer’s diagnostic.
- New test uses VeraBIND™ technology to detect tau pathology for early disease intervention.
- Affordable, accessible alternative to tau PET imaging, enabling diagnosis in early disease stages.
- Targets 92% of mild cognitive impairment cases that remain undiagnosed.
Source: Business Wire
Notable Quotes
- “Scientific discovery and therapeutic development in Alzheimer’s disease are surging, offering clinicians viable new opportunities to intervene early, potentially slow Alzheimer’s disease progression, and improve quality of life for patients.” — Khalid Iqbal, Ph.D., Chief Scientific Officer at Phanes Biotech
- “Our technology has the potential to eliminate the uncertainties and accessibility hurdles of current Alzheimer’s disease diagnostics for the benefit of clinicians diagnosing and treating AD, their patients, and researchers conducting clinical trials.” — Josh Soldo, Chief Scientific Officer at Veravas
SoHC's Take
The Veravas-Phanes Biotech collaboration marks a significant advancement in Alzheimer’s diagnostics by addressing the accessibility and affordability gaps that currently hinder early diagnosis and intervention. By focusing on tau pathology, a key biomarker in AD, their test aligns with evolving therapeutic approaches that prioritize early-stage treatment. This innovation holds the potential to redefine the diagnostic landscape, allowing for widespread use in clinical settings, thus empowering more precise and timely medical decision-making for millions at risk.
